The debate continues.
Industry experts share their favorite biotech plays for this year.
Low payout ratios imply not only a highly sustainable dividend but also provide the company with a high level of dividend growth potential.
In the absence of hard-hitting analysis and rigor, the media and traders will rely on faux indicators as a crutch.
Much of the truly horrendous and contractionary macroeconomic data over the past three weeks or so were released after the December Fed meeting.
These chip stocks are setting up well for a successful 2023, according experts in the space.
The market debuts with a bang, ends with a whimper.
We are slightly more encouraged for clearer skies for the equity indexes after Tuesday.
Let's check the market's technicals as we start 2023.
The business relationship between the U.S. and China is changed forever. That removes many of the margin-increasing benefits of globalism from the corporate profit proposition.